MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
common stock through...
$2,951K
Net cash provided by
(used in) financing...
$2,951K
Increase (decrease) in
cash, cash...
-$122K
Canceled cashflow
$2,951K
Accounts receivable
-$1,253K
Accretion of liability
related to sale of future...
$814K
Stock-based compensation
expense
$749K
Accounts payable
$510K
Non-cash operating lease
expense
$185K
Other non-cash items,
net
$49K
Depreciation and
amortization expense
$29K
Net cash used in
operating activities
-$3,073K
Canceled cashflow
$3,589K
Net income (loss)
-$4,145K
Other current assets
$1,336K
Accrued compensation
-$642K
Operating lease
liabilities
-$285K
Other current
liabilities
-$166K
Accrued research and
development expenses
-$41K
Deferred revenue
-$32K
Other assets
$15K
Back
Back
Cash Flow
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)
source: myfinsight.com